Keywords: aventis, amaryl, launched, japan, its, third-generation, sulfonylurea
Aventis' Amaryl launched in Japan
Article | 18 April 2000
Aventis has launched its third-generation sulfonylurea drug Amaryl(glimepiride) in Japan for the treatment of patients with type 2 diabetes mellitus. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
